Drugs / Decitabine-primed Tandem CAR19/20 engineered T cells
Decitabine-primed Tandem CAR19/20 engineered T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04553393 | Sep 2020 → Sep 2021 | aggressive B-cell non-Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine-primed Tandem CAR19/20 engineered T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04553393 ↗ |
| Modality | Cell therapy | “decitabine-primed CAR-T cells” NCT04553393 ↗ |